Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin

计划入组 20 人 · 首次发布于 2021 年 9 月 9 日

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

计划入组 233 人 · 首次发布于 2019 年 2 月 15 日

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

计划入组 50 人 · 首次发布于 2025 年 7 月 20 日

Chronic Pruritus(Alys)

unknown

MRGPRX4 (pruritus)

Kineta Chronic Pain LLC

United States

Origin Biosciences, Inc.

United States

Origin Investment Corp I

Galderma Launches Phase II Trials of Nemolizumab for Systemic Sclerosis and Chronic Pruritus of Unknown Origin

Galderma Initiates Phase II Trial of Nemolizumab for Chronic Pruritus of Unknown Origin

Attovia Therapeutics Initiates Phase 1 Trial of Novel Anti-IL-31 Therapy for Chronic Pruritus